{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:53:56Z","timestamp":1778104436900,"version":"3.51.4"},"reference-count":84,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK-9) inhibitors are a group of drugs whose main mechanism of action is binding to the PCSK-9 molecule, which reduces the degradation of the low-density lipoprotein receptor (LDL-R) and, hence, increases the uptake of low-density lipoprotein cholesterol (LDLc) from the bloodstream as well as reducing its concentration. The effectiveness of three monoclonal antibodies, namely, alirocumab (human IgG1\/\u03ba monoclonal antibody, genetically engineered in Chinese hamster ovary cells), evolocumab (the first fully human monoclonal antibody), and bococizumab (humanized mouse antibody), in inhibiting the action of PCSK-9 and reducing LDLc levels has been confirmed. The first two, after clinical trials, were approved by the Food and Drug Administration (FDA) and are used primarily in the treatment of autosomal familial hypercholesterolemia and in cases of statin intolerance. They are currently used both as monotherapy and in combination with statins and ezetimibe to intensify therapy and achieve therapeutic goals following the American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines. However, the lipid-lowering effect is not the only effect of action described by researchers that PCSK-9 inhibitors have. This paper is a review of the literature describing the pleiotropic effects of PCSK-9 inhibitors, which belong to a group of drugs that are being increasingly used, especially when standard lipid-lowering therapy fails. The article focuses on activities other than lipid-lowering, such as the anti-atherosclerotic effect and stabilization of atherosclerotic plaque, the anti-aggregation effect, the anticoagulant effect, the antineoplastic effect, and the ability to influence the course of bacterial infections. In this publication, we try to systematically review the current scientific data, both from our own scientific work and knowledge from international publications.<\/jats:p>","DOI":"10.3390\/ijms22063144","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T11:18:38Z","timestamp":1616152718000},"page":"3144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Pleiotropic Effects of PCSK-9 Inhibitors"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0674-5612","authenticated-orcid":false,"given":"Marcin","family":"Basiak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-463X","authenticated-orcid":false,"given":"Micha\u0142","family":"Kosowski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Cyrnek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-5516","authenticated-orcid":false,"given":"\u0141ukasz","family":"Bu\u0142dak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Malig\u0142\u00f3wka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9081-0984","authenticated-orcid":false,"given":"Grzegorz","family":"Machnik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-2906","authenticated-orcid":false,"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyk\u00f3w 18, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK-9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","article-title":"Molecular basis of PCSK-9 function","volume":"203","author":"Lambert","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK-9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK-9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2014.02.538","article-title":"Elevated plasma PCSK 9 levels are equally detrimental for patients with non familial hypercholesterolemia and heterozygous familial hypercholesterolemia irrespective of low density lipoprotein receptor defects","volume":"63","author":"Lambert","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","article-title":"Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the Proprotein Convertase Subtilisin\/Kexin Type 9 for treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effects of the lipoprotein convertase subtilisin\/Kexin 9 monoclonal antibody AMG 145 in homozygous familial hypercholestermia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti PCSK 9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS 2 randomized, placebo controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","article-title":"Effects of a monoclonal antibody to PCSK 9 Reg N 727\/SAR 236553 to reduce low density lipoprotein cholesterol in patients with heterozygous familial hypercholestremia on stable statin dose with or without ezetimibe therapy: A phase 2 randomized controlled trial","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"ref_11","unstructured":"Robinson, J.G. (September, January 30). Hot line II. Coronary artery disease and lipids. Proceedings of the European Society of Cardiology Congress, Barcelona, Spain."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrneph.2017.51","article-title":"The immunology of atherosclerosis","volume":"13","author":"Hansson","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: Biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","first-page":"e167086","article-title":"Statins as modulators of regulatory T-cell biology","volume":"2013","author":"Gutierrez","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.jacc.2014.01.054","article-title":"Innate and adaptive inflammation as a therapeutic target in vascular disease: The emerging role of statins","volume":"63","author":"Tousoulis","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2017.10.013","article-title":"The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials","volume":"17","author":"Li","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e022348","DOI":"10.1136\/bmjopen-2018-022348","article-title":"Impact of PCSK-9 monoclonal antibodies on circulating hs-CRP levels: A systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Cao","year":"2018","journal-title":"BMJ Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK-9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-\u03baB activation in THP-1-derived P-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK-9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK-9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Neele","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbrc.2017.02.085","article-title":"PCSK-9 regulates the chemokine receptor CCR2 on monocytes","volume":"485","author":"Grune","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/eurheartj\/ehx098","article-title":"Cholesterol, CCR2, and monocyte phenotypes in atherosclerosis","volume":"38","author":"Nahrendorf","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/14017431.2020.1775878","article-title":"Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: An unused potential?","volume":"54","author":"Hovland","year":"2020","journal-title":"Scand. Cardiovasc. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbadis.2015.03.001","article-title":"Sirtuins in vascular diseases: Emerging roles and therapeutic potential","volume":"1852","author":"Vitiello","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/M15-2994","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 monoclonal antibodies for acute coronary syndrome: A narrative review","volume":"164","author":"Navarese","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK-9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jcmg.2020.02.019","article-title":"Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy","volume":"13","author":"Omori","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2018.06.132","article-title":"Influence of PCSK9 inhibition on the stabilization of atherosclerotic plaque determined by biochemical methods and magnetic resonance imaging","volume":"275","author":"Basiak","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.atherosclerosis.2018.06.807","article-title":"The effect of PCSK9 inhibition on biomarkers of atherosclerotic plaque destabilization release in patient with dyslipidemia","volume":"275","author":"Basiak","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.hjh.0000539739.88116.6b","article-title":"Influence of PCSK9 inhibition on the stabilization of atherosclerotic plaque determined by biochemical methods and magnetic resonance imaging","volume":"36","author":"Basiak","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.hjh.0000539573.94426.d8","article-title":"The effect of PCSK9 inhibition on biomarkers of atherosclerotic plaque destabilization release in hypertensive patients with dyslipidemia","volume":"36","author":"Basiak","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.117.033254","article-title":"Mortality differences associated with treatment responses in CANTOS and FOURIER: Insight and implications","volume":"137","author":"Ridker","year":"2018","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDLc and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150\u2009mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/CIRCRESAHA.108.172064","article-title":"A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein","volume":"102","author":"Chen","year":"2008","journal-title":"Circ. Res."},{"key":"ref_39","first-page":"30171","article-title":"Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases","volume":"S1537\u2013S1891","author":"Hofmann","year":"2017","journal-title":"Vascul. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood-2014-05-574491","article-title":"Oxidized LDL activates blood platelets through CD36\/NOX2-mediated inhibition of the cGMP\/protein kinase G signaling cascade","volume":"125","author":"Magwenzi","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10557-011-6324-6","article-title":"The discovery of LOX-1, its ligands and clinical significance","volume":"25","author":"Yoshimoto","year":"2011","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2015-08-664300","article-title":"Novel phosphatidylethanolamine derivatives accumulate in circulation in hyperlipidemic ApoE-\/- mice and activate platelets via TLR2","volume":"127","author":"Biswas","year":"2016","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK-9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/jtd.2017.01.40","article-title":"Lipoprotein(a) and inhibitors of proprotein convertase subtilisin\/kexin type 9","volume":"9","author":"Kotani","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2014.08.041","article-title":"LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism","volume":"237","author":"Carnevale","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2017.06.119","article-title":"Effects of PCSK-9 inhibitors on platelet function in adults with hypercholesterolemia","volume":"263","author":"Barale","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.1999.01317.x","article-title":"Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study","volume":"105","author":"Rumley","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/1076029615571630","article-title":"Factoring in factor VIII with acute ischemic stroke","volume":"21","author":"Siegler","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2141.1990.tb07793.x","article-title":"Haemophilia protects against ischaemic heart disease: A study of risk factors","volume":"75","author":"Rosendaal","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"37685","DOI":"10.1074\/jbc.274.53.37685","article-title":"Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism","volume":"274","author":"Saenko","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2004-11-4230","article-title":"LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo","volume":"106","author":"Bovenschen","year":"2005","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1182\/blood-2010-03-277079","article-title":"Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile","volume":"116","author":"Martinelli","year":"2010","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/eurheartj\/ehy014","article-title":"Rosuvastatin use improves measures of coagulation in patients with venous thrombosis","volume":"39","author":"Biedermann","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2014.07.048","article-title":"Mechanism of action of anti-hypercholesterolemia drugs and their resistance","volume":"741","author":"Tiwari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.metabol.2010.08.013","article-title":"Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: A possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression","volume":"60","author":"Moon","year":"2011","journal-title":"Metabolism"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1160\/TH09-04-0274","article-title":"C-reactive protein and venous thromboembolism. A prospectiveinvestigation in the ARIC cohort","volume":"102","author":"Folsom","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa022157","article-title":"An association between atherosclerosis and venous thrombosis","volume":"348","author":"Prandoni","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.amjmed.2007.01.029","article-title":"Lipoprotein (a) and venous thromboembolism in adults: A meta-analysis","volume":"120","author":"Sofi","year":"2007","journal-title":"Am. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK-9Inhibition, and Cardiovascular Risk","volume":"139","author":"Fazio","year":"2019","journal-title":"Circulation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral Artery Disease and Venous Thromboembolic Events after Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fimmu.2013.00387","article-title":"Targeting toll-like receptors: Promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases","volume":"4","author":"Savva","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/CMR.16.3.379-414.2003","article-title":"Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock","volume":"16","author":"Kuiper","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK-9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","article-title":"Differential expression of PCSK-9 modulates infection, inflammation and coagulation in a murine model of sepsis","volume":"46","author":"Dwivedi","year":"2016","journal-title":"Shock"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Cheng, H.Y., Wu, R., Gebre, A.K., Hanna, R.N., Smith, D.J., Parks, J.S., Ley, K., and Hedrick, C.C. (2013). Increased cholesterol content in gamma-delta (\u03b3\u03b4) T lymphocytes differentially regulates their activation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063746"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Arama, C., Diarra, I., Kouriba, B., Sirois, F., Fedoryak, O., Thera, M.A., Coulibaly, D., Lyke, K.E., Plowe, C.V., and Chr\u00e9tien, M. (2018). Malaria severity: Possible influence of the E670G PCSK-9 polymorphism: A preliminary case-control study in Malian children. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192850"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1017\/S1368980015000646","article-title":"The association between serum lipids and colorectal neoplasm: A systemic review and meta-analysis","volume":"18","author":"Tian","year":"2015","journal-title":"Public Health Nutr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/aje\/kwv294","article-title":"Blood lipid concentrations and colorectal adenomas: A systematic review and meta-analysis of colonoscopy studies in Asia, 2000\u20132014","volume":"183","author":"Passarelli","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41467-018-06467-9","article-title":"A Mendelian randomization study of the effects of blood lipids on breast cancer risk","volume":"9","author":"Nowak","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3892\/etm.2017.4218","article-title":"PCSK-9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways","volume":"13","author":"Xu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_73","first-page":"2787","article-title":"PCSK-9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways","volume":"8","author":"Piao","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5114\/aoms.2019.84732","article-title":"Potential anti-tumor effect of a nanoliposomal antiPCSK-9 vaccine in mice bearing colorectal cancer","volume":"15","author":"Nik","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"570","DOI":"10.5114\/aoms.2019.84734","article-title":"Effects of immunization against PCSK-9 in an experimental model of breast cancer","volume":"15","author":"Nik","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccinethattargetsPCSK-9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","article-title":"A Therapeutic Peptide Vaccine Against PCSK9","volume":"7","author":"Pan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10557-020-07041-6","article-title":"PCSK9Q\u03b2-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice","volume":"35","author":"Wu","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK-9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","article-title":"FOURIER Investigators. Cognition After Lowering LDL-Cholesterol with Evolocumab","volume":"75","author":"Gencer","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jacl.2018.01.004","article-title":"Long-term efficacy and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials","volume":"12","author":"Bai","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","article-title":"Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results from the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study","volume":"117","author":"Blom","year":"2015","journal-title":"Circ. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/6\/3144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:38:07Z","timestamp":1760161087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/6\/3144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":84,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijms22063144"],"URL":"https:\/\/doi.org\/10.3390\/ijms22063144","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]}}}